Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/HCO.0000000000000848 http://scihub22266oqcxt.onion/10.1097/HCO.0000000000000848 33720052!8048730!33720052     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Cardiol 2021 ; 36 (3): 340-351 Nephropedia Template TP {{tp|p=33720052|t=2021. Are the current evaluation tools for advanced therapies biased?|pdf=|usr=}}{{33720052}} gab.com Text Are the current evaluation tools for advanced therapies biased JO: Curr Opin Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33720052 #FOAvip PURPOSE OF REVIEW: Despite attention to racial disparities in outcomes for heart failure (HF) and other chronic diseases, progress against these inequities has been gradual at best. The disparities of COVID-19 and police brutality have highlighted the pervasiveness of systemic racism in health outcomes. Whether racial bias impacts patient access to advanced HF therapies is unclear. RECENT FINDINGS: As documented in other settings, racial bias appears to operate in HF providers' consideration of patients for advanced therapy. Multiple medical and psychosocial elements of the evaluation process are particularly vulnerable to bias. SUMMARY: Reducing gaps in access to advanced therapies will require commitments at multiple levels to reduce barriers to healthcare access, standardize clinical operations, research the determinants of patient success and increase diversity among providers and researchers. Progress is achievable but likely requires as disruptive and investment of immense resources as in the battle against COVID-19. Twit Text FOAVip Are the current evaluation tools for advanced therapies biased ????Curr Opin Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33720052 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33720052 #FOAvip English Wikipedia <ref>{{Cite pmid|33720052}}</ref> Are the current evaluation tools for advanced therapies biased? #MMPMID33720052 Givens RC Curr Opin Cardiol 2021[May]; 36 (3): 340-351 PMID33720052show ga PURPOSE OF REVIEW: Despite attention to racial disparities in outcomes for heart failure (HF) and other chronic diseases, progress against these inequities has been gradual at best. The disparities of COVID-19 and police brutality have highlighted the pervasiveness of systemic racism in health outcomes. Whether racial bias impacts patient access to advanced HF therapies is unclear. RECENT FINDINGS: As documented in other settings, racial bias appears to operate in HF providers' consideration of patients for advanced therapy. Multiple medical and psychosocial elements of the evaluation process are particularly vulnerable to bias. SUMMARY: Reducing gaps in access to advanced therapies will require commitments at multiple levels to reduce barriers to healthcare access, standardize clinical operations, research the determinants of patient success and increase diversity among providers and researchers. Progress is achievable but likely requires as disruptive and investment of immense resources as in the battle against COVID-19. |*COVID-19[MESH] |*Racism[MESH] |Health Services Accessibility[MESH] |Humans[MESH]Are the current evaluation tools for advanced therapies biased?(epmc).pdf DeepDyve Pubget Overpricing